Imagens apenas para referência
BAV199,215
+Lista de MateriaisDIODE ARRAY GP 75V 160MA TO236AB
-
FabricanteNexperia USA Inc.
-
Peça do Fabricante #BAV199,215
-
Ficha Técnica BAV199,215 DataSheet
-
Em Estoque3723
365 Garantia de Qualidade em 1 dia
7*24 Garantia de serviço em 24 horas
90-Garantia de pós-venda em 1 dia
Garantia de Produto Genuíno
Especificações
| Atributo | Valor |
| PartStatus | Active |
| DiodeConfiguration | 1 Pair Series Connection |
| Technology | Standard |
| Voltage-DCReverse(Vr)(Max) | 75 V |
| Current-AverageRectified(Io)(perDiode) | 160mA (DC) |
| Voltage-Forward(Vf)(Max)@If | 1.25 V @ 150 mA |
| Speed | Small Signal =< 200mA (Io), Any Speed |
| ReverseRecoveryTime(trr) | 3 µs |
| Current-ReverseLeakage@Vr | 5 nA @ 75 V |
| OperatingTemperature-Junction | 150°C (Max) |
| MountingType | Surface Mount |
| Package/Case | TO-236-3, SC-59, SOT-23-3 |
| SupplierDevicePackage | TO-236AB |
| BaseProductNumber | BAV199 |
Visão Geral
Description
BAV199 and BAV215 are investigational drugs designed to target specific pathways involved in various cancers. BAV199 is a selective inhibitor of the protein MDM2, which plays a crucial role in regulating the p53 tumor suppressor pathway. By inhibiting MDM2, BAV199 aims to reactivate p53 function, leading to increased apoptosis in cancer cells.
BAV215, on the other hand, is an advanced formulation that may focus on enhancing the delivery and efficacy of cancer treatments through improved pharmacokinetics or targeting specific tumor microenvironments. Both compounds are part of a broader strategy to develop novel cancer therapies that can overcome resistance mechanisms and improve patient outcomes.
Clinical trials are ongoing to evaluate their safety, tolerability, and effectiveness in various oncology settings. The results of these studies will help determine their potential roles in cancer treatment regimens.
BAV215, on the other hand, is an advanced formulation that may focus on enhancing the delivery and efficacy of cancer treatments through improved pharmacokinetics or targeting specific tumor microenvironments. Both compounds are part of a broader strategy to develop novel cancer therapies that can overcome resistance mechanisms and improve patient outcomes.
Clinical trials are ongoing to evaluate their safety, tolerability, and effectiveness in various oncology settings. The results of these studies will help determine their potential roles in cancer treatment regimens.
Equivalent
The BAV199 and BAV215 are general-purpose switching diodes. Equivalent products include:
- 1N4148
- 1N4001
- 1N5231 (for Zener applications)
For specific replacements, consider datasheets for characteristics like forward voltage, reverse voltage, and current ratings to ensure compatibility.
- 1N4148
- 1N4001
- 1N5231 (for Zener applications)
For specific replacements, consider datasheets for characteristics like forward voltage, reverse voltage, and current ratings to ensure compatibility.
Features
BAV199 and BAV215 are monoclonal antibodies designed to target the immune system, specifically targeting the PD-1 pathway to enhance anti-tumor immunity.
BAV199 is notable for its potential application in cancer immunotherapy, aiming to improve the immune response against tumors by blocking the PD-1 receptor, thereby allowing T cells to effectively attack cancer cells.
BAV215, on the other hand, is a biosimilar to a well-established PD-1 inhibitor. While it shares similar efficacy and safety profiles with the reference product, it may offer a more cost-effective option for patients, enhancing accessibility to PD-1 targeting therapies.
Both antibodies are being investigated for their roles in various malignancies, including melanoma, non-small cell lung cancer, and other solid tumors. Their development focuses on improving patient outcomes and expanding treatment options in cancer therapy.
BAV199 is notable for its potential application in cancer immunotherapy, aiming to improve the immune response against tumors by blocking the PD-1 receptor, thereby allowing T cells to effectively attack cancer cells.
BAV215, on the other hand, is a biosimilar to a well-established PD-1 inhibitor. While it shares similar efficacy and safety profiles with the reference product, it may offer a more cost-effective option for patients, enhancing accessibility to PD-1 targeting therapies.
Both antibodies are being investigated for their roles in various malignancies, including melanoma, non-small cell lung cancer, and other solid tumors. Their development focuses on improving patient outcomes and expanding treatment options in cancer therapy.
Pinout
The BAV199 and BAV215 are dual switching diodes, housed in a standard TO-92 package. Both devices have a total of 3 pins.
Pin Functions:
1. Pin 1 (Anode of Diode 1): Connects to the positive side for the first diode.
2. Pin 2 (Common Cathode): This pin is connected to the cathodes of both diodes, serving as a common connection point.
3. Pin 3 (Anode of Diode 2): Connects to the positive side for the second diode.
These diodes are typically used in various applications such as signal processing, switching, and protection circuits. The BAV199 has a higher reverse voltage rating compared to the BAV215, making it suitable for different circuit requirements.
Pin Functions:
1. Pin 1 (Anode of Diode 1): Connects to the positive side for the first diode.
2. Pin 2 (Common Cathode): This pin is connected to the cathodes of both diodes, serving as a common connection point.
3. Pin 3 (Anode of Diode 2): Connects to the positive side for the second diode.
These diodes are typically used in various applications such as signal processing, switching, and protection circuits. The BAV199 has a higher reverse voltage rating compared to the BAV215, making it suitable for different circuit requirements.
Manufacturer
The BAV199 and BAV215 are manufactured by NXP Semiconductors, a global semiconductor company. NXP specializes in creating secure connectivity solutions for embedded applications, serving various sectors including automotive, industrial, and consumer electronics. The company was formed in 2006 from the semiconductor division of Philips and has since become a leading provider of chips and technologies. NXP's products are widely used in applications such as radio frequency identification (RFID), automotive safety systems, mobile payment systems, and Internet of Things (IoT) devices. The BAV199 and BAV215 are specifically signal switching diodes, utilized in various electronic circuits for their efficiency and reliability in handling small signal applications.
Application
BAV199 and BAV215 are monoclonal antibodies that target the C5 complement component, primarily used in research and clinical applications related to complement-mediated conditions. Their application areas include:
1. Autoimmune Diseases: Treatment of diseases like lupus or myasthenia gravis where complement activation plays a role.
2. Neurological Disorders: Potential use in conditions such as Alzheimer's disease.
3. Transplant Rejection: Prevention of acute rejection by inhibiting complement activation.
4. Rare Blood Disorders: Management of conditions like paroxysmal nocturnal hemoglobinuria.
Both antibodies are being investigated for efficacy and safety in clinical trials across these areas.
1. Autoimmune Diseases: Treatment of diseases like lupus or myasthenia gravis where complement activation plays a role.
2. Neurological Disorders: Potential use in conditions such as Alzheimer's disease.
3. Transplant Rejection: Prevention of acute rejection by inhibiting complement activation.
4. Rare Blood Disorders: Management of conditions like paroxysmal nocturnal hemoglobinuria.
Both antibodies are being investigated for efficacy and safety in clinical trials across these areas.
Package
The BAV199 and BAV215 are typically available in DO-35 glass package types. These are axial leaded packages commonly used for signal and switching applications in electronic circuits.
